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BACKGROUND: We determined how CXC-chemokine signalling and necrosis factor-kB (NF-kB) activity affected heat-shock protein
90 (Hsp90) inhibitor (geldanamycin (GA) and 17-allylamino-demethoxygeldanamycin (17-AAG)) cytotoxicity in castrate-resistant
prostate cancer (CRPC).
METHODS: Geldanamycin and 17-AAG toxicity, together with the CXCR2 antagonist AZ10397767 or NF-kB inhibitor BAY11-7082,
was assessed by 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide assay in two CRPC lines, DU145 and PC3. Flow
cytometry quantified apoptotic or necrosis profiles. Necrosis factor-kB activity was determined by luciferase readouts or indirectly by
quantitative PCR and ELISA-based determination of CXCL8 expression.
RESULTS: Geldanamycin and 17-AAG reduced PC3 and DU145 cell viability, although PC3 cells were less sensitive. Addition of
AZ10397767 increased GA (e.g., PC3 IC20: from 1.67±0.4 to 0.18±0.2nM) and 17-AAG (PC3 IC20: 43.7±7.8 to 0.64±1.8nM)
potency in PC3 but not DU145 cells. Similarly, BAY11-7082 increased the potency of 17-AAG in PC3 but not in DU145 cells,
correlating with the elevated constitutive NF-kB activity in PC3 cells. AZ10397767 increased 17-AAG-induced apoptosis and
necrosis and decreased NF-kB activity/CXCL8 expression in 17-AAG-treated PC3 cells.
CONCLUSION: Ansamycin cytotoxicity is enhanced by inhibiting NF-kB activity and/or CXC-chemokine signalling in CRPC cells.
Detecting and/or inhibiting NF-kB activity may aid the selection and treatment response of CRPC patients to Hsp90 inhibitors.
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There has been considerable interest in the clinical application
of inhibitors of heat-shock protein 90 (Hsp90), particularly in
cancer therapeutics (Smith et al, 1998; Maloney and Workman,
2002; Isaacs et al, 2003; Workman, 2004; Solit and Rosen, 2006).
Heat-shock protein 90 is a molecular chaperone protein, the
function of which is to ensure the correct folding of a well-defined
group of client proteins, many of which have been shown to have a
role in tumourigenesis (Jolly and Morimoto, 2000). Depending on
its conformation, Hsp90 recruits various co-chaperones to
assemble two distinct complexes, one of which favours protea-
some-dependent degradation of the client protein and one that
favours stabilisation (Meyer et al, 2003). Several classes of
Hsp90 inhibitors have been developed, but the majority of
research to date has been conducted exploiting the ansamycin
class of inhibitors, of which the natural product geldanamycin
(GA) and its synthetic analogue, 17-allylamino-demethoxygelda-
namycin (17-AAG), are the best-known molecules. Geldanamycin
and 17-AAG stabilise an Hsp90 conformation that recruits
co-chaperones to target Hsp90 client proteins for proteasomal
degradation (Mimnaugh et al, 1996; Roe et al, 1999). Both
inhibitors have shown preclinical activity in a range of human
cancer models, but GA was too toxic in animal testing to progress
into the clinic. Furthermore, recent phase I clinical trials with
17-AAG or its primary metabolite, 17-dimethylaminoethylamino-
17-demethoxygeldananmycin (17-DMAG), have determined
tolerable toxicity with these agents and reported prolonged stable
disease in treated patients (Maloney and Workman, 2002; Sausville
et al, 2003; Pacey et al, 2006; Ramanthan et al, 2007; Solit et al,
2007; Pacey et al, 2009).
17-Allylamino-demethoxygeldanamycin has been shown to
exhibit activity in a number of prostate cancer (CaP) models
(Solit et al, 2002; Solit and Rosen, 2003). Although many CaP
patients initially respond to therapy, a significant proportion of
patients relapse after radiation therapy and/or androgen ablation
therapy, leading to the acquisition of a castration-resistant,
metastatic disease. Treatment options for patients with castra-
tion-resistant, metastatic CaP are very limited, principally because
of the intrinsic chemoresistance acquired by cells during disease
progression on therapy. Therefore, the potential to use Hsp90
inhibitors in this disease setting is an exciting and important
prospect; treatment responses to 17-DMAG have been reported in
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and 33 months in a phase I trial (Pacey et al, 2009).
CXCL8 (also known as interleukin-8) is a CXC chemokine that
modulates the function of target cells through activation of two
receptors, CXCR1 and CXCR2, which have a similar affinity for
CXCL8 but otherwise exhibit markedly different selectivity for
related CXC chemokines (Waugh and Wilson, 2008). Increased
expression of CXCL8, CXCR1 and CXCR2 genes has been detected
in CaP tissue through the exploitation of in situ hybridisation
(Uehara et al, 2005) and/or immunohistochemistry (Murphy et al,
2005; Huang et al, 2005a), whereas increased levels of CXCL8 have
been detected in the serum of patients with pathologically
confirmed CaP (Veltri et al, 1999). Therefore, CaP cells and
tumour stromal cells are subject to an increased CXC-chemokine
signalling stimulus within the tumour microenvironment, under-
pinning a range of tumour-promoting functions (Waugh and
Wilson, 2008; Waugh et al, 2008). In the context of CaP, CXCL8
expression correlates with increased angiogenesis, tumourigenicity
and lymph node metastasis in vivo (Inoue et al, 2000; Kim et al,
2001). We, along with others, have shown that CXCL8 signalling
contributes to the transition of a disease to a castration-resistant
state (Araki et al, 2007; Seaton et al, 2008). Furthermore, we have
shown that CXC-chemokine signalling (including CXCL8)
modulates the sensitivity of CaP cells to environmental stresses
such as hypoxia and chemotherapy agents, including the
DNA-damage agents oxaliplatin and etoposide (Maxwell et al,
2007; Wilson et al, 2008a).
17-Allylamino-demethoxygeldanamycin has been shown to
enhance the cytotoxicity of several conventional chemotherapeutic
drugs in representative cell-based models of colorectal cancer and
CaP (Munster et al, 2001; Rakitina et al, 2003; Vasilevskaya and
O’Dwyer, 2005). The capacity of 17-AAG to reduce the activation of
NF-kB has been proposed as a potential mode of action in
sensitising cancer cells to oxaliplatin and 5-FU (Rakitina et al,
2003). However, the relevance of constitutive or ligand-induced
NF-kB activity in directly regulating the sensitivity of cancer cells
to Hsp90 inhibitors has not been studied extensively. Increased
NF-kB activity has been reported in CaP cell lines and tissue
(Fradet et al, 2004; Sweeney et al, 2004; Li et al, 2005; Huang et al,
2005b). Therefore, as Hsp90 inhibitors hold promise in treating
CRPC, the objective of this study was to determine whether the
intrinsic levels of NF-kB activity and/or constitutive CXC-
chemokine signalling may correlate with and modulate the efficacy
of Hsp90-targeted therapies in CRPC cells.
MATERIALS AND METHODS
Cell culture
PC3 and DU145 cells were sourced and cultured as previously
described (MacManus et al, 2007; Maxwell et al, 2007).
Chemical and reagents
Chemicals were sourced from Sigma-Aldrich (St Louis, MO, USA),
unless otherwise stated. BAY11-7082 was purchased from Calbio-
chem (La Jolla, CA, USA). AZ10397767 ((1R)-5-[[(3-chloro-2-
fluorophenyl)methyl]thio]-7-[[2-hydroxy-1-methylethyl]amino]
thiazolo[4,5-d]pyrimidin-2(3H)-one) was kindly provided by Dr
Simon Barry and Dr David Blakey (AstraZeneca, Alderley Park,
Cheshire, UK) (Walters et al, 2007).
3,30-dihexyloxacarbocyanine iodide and propidium iodide
staining
Cells were seeded into 24-well plates (1 10
5 cells per well) in
RPMI 1640 medium and allowed to attach overnight. The CXCR2
antagonist AZ10397767 (20nM) was added to the cells in
conjunction with 17-AAG (1nM or 1mM). Plates were incubated
in a humidified chamber at 371C with 5% CO2 for 72h; thereafter,
3,30-dihexyloxacarbocyanine iodide (DiOC6(3)) (40nM) was added
and the plates were incubated for a further 15min. Propidium
iodide (PI) (20mgml
 1) was added, plates were returned to the
incubator for 10min and cells were collected (floating and
adherent cells removed by trypsin). The cells were washed once
in PBS and re-suspended in 500ml PBS and analysed by flow
cytometry (Beckman Coulter, Buckinghamshire, UK). Plots of FL1
(DiOC6(3)) vs FL4 (PI) were divided into quadrants to assess the
percentage of cells living, cells undergoing necrosis and cells at
early and late stages of apoptosis (Lecoeur et al, 2008).
Quantitative real-time PCR
RNA was harvested and prepared for analysis by quantitative real-
time (qPCR) as previously described (Wilson et al, 2008a). The
cDNA (50ng) was mixed with primers (2nM), sterile water and
SYBR Green PCR mastermix (Finnzymes Diagnostics, Espoo,
Finland). The primer sequences were as follows: 18s: forward:
50-CATTCGTATTGCGCCGCT-30, reverse: 50-CGACGGTATCTGA
TCGTC-30; HSP90: forward: 50-AAAGCCCATCTGGACCAGAA-30,
reverse: 50-AGCACGTCGTGGGACAAATA-30. Primers for CXCL8
have been described previously. Standard cycling procedures were
used with an annealing temperature of 551C and an amplification
temperature of 951C. Specific amplicon formation with each
primer pair was confirmed by melt curve analysis, and gene
expression was quantified relative to an 18s housekeeping gene.
Immunoblotting
Protein was prepared, resolved and blotted as described previously
(Murphy et al, 2005; MacManus et al, 2007). Membranes were
washed in Tris-buffered saline/0.1% Tween-20 (TBS-T), then
blocked for 1h at room temperature in 5% bovine serum
albumin/TBS-T (BSA/TBS-T). Expression of Hsp90 was detected
using an anti-human Hsp90 Ab (Cell Signaling Technology Inc,
Danvars, MA, USA) at 1:1000 dilution in 5% BSA/TBS-T. The
membranes were washed thrice in TBS-T and then incubated with
a rabbit horse-radish peroxidase (HRP)-labelled secondary anti-
body (GE Healthcare UK Ltd, Buckinghamshire, UK). After three
washes in TBS-T, the bands were detected using enhanced
chemiluminescence (ECL plus reagents, Amersham Biosciences,
Amersham, UK). Membranes were re-probed to ensure equal
loading with GAPDH antibody (Biogenesis, Dorset, UK).
3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium
bromide cell viability assays
Cells were seeded into 96-well plates (3 10
3 cells per well) in
RPMI 1640 medium and allowed to attach overnight. Serial
dilutions of 17-AAG or GA were added to the cells alone or in
combination with AZ10397767 (20nM). Plates were incubated in a
humidified chamber at 371C with 5% CO2 for 72h; thereafter, 50ml
3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
(MTT) (2mgml
 1) was added and the plates were returned to
the incubator for 4h. Medium and any non-metabolised MTT was
aspirated from the wells and formazan crystals were dissolved in
100ml dimethyl sulphoxide. Absorbance was read at 570nm using
a microplate reader (Molecular Devices, Wokingham, UK). Data
were plotted using a nonlinear regression curve fitting algorithm
(GraphPad Prism 4.0, La Jolla, CA, USA).
Luciferase reporter assays
The detection of NF-kB-driven transcriptional activity in unsti-
mulated cells was determined using the NF-kB-LUC-pGL3 plasmid
as previously described (Wilson et al, 2008a).
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Student’s t-test was used to compare means where appropriate. All
tests were two-tailed.
RESULTS
Inhibition of constitutive CXC-chemokine signalling
confers cell-specific ansamycin-induced cytotoxicity in
CRPC cells
Our experiments were conducted on two representative models of
CRPC, the PC3 and DU145 cell lines. 3-(4, 5 -Dimethylthiazol-2-
yl)-2, 5-diphenyltetrazolium bromide assays demonstrated that
PC3 cells were differentially sensitive to GA and 17-AAG, with GA
exhibiting greater activity (Figure 1A and B; Table 1). In contrast,
DU145 cells were equally sensitive to these two agents (Figure 1C
and D; Table 1). Interestingly, the DU145 cell line was also found to
be markedly more sensitive to these ansamycin-based compounds
in comparison with PC3 cells; GA was 17-fold more potent in
DU145 cells, whereas the potency of 17-AAG was 275-fold greater
in DU145 cells compared with PC3 cells.
We previously showed that inhibition of CXCR2 signalling can
increase the sensitivity of CaP cells to conventional cytotoxic
chemotherapeutic agents and death receptor ligands (Wilson et al,
2008a,b). Therefore, we determined whether blockade of consti-
tutive CXC-chemokine signalling using the CXCR2 receptor
antagonist, AZ10397767, sensitised PC3 and DU145 cells to GA
and 17-AAG. AZ10397767 was administered to cells concurrently
at a concentration of 20nM, exploiting its selectivity to block
CXCR2 signalling. Addition of AZ10397767 to PC3 cells enhanced
the cytotoxicity of both Hsp90 inhibitors, increasing the potency
(IC50) of GA and of 17-AAG by three-fold and 3.5-fold, respectively
(Table 1). However, analysis of data using nonlinear regression
illustrated that the augmentation of 17-AAG cytotoxicity in PC3
cells was more striking at lower concentrations, wherein the
calculated IC20 value was observed to have increased 68-fold after
co-administration of AZ10397767 with 17-AAG. In marked
contrast, the inhibition of CXCR2 signalling did not increase the
cytotoxicity of either GA or 17-AAG in DU145 cells.
Inhibition of CXCR2 signalling potentiates 17-AAG-
cytotoxicity through promotion of increased apoptosis and
necrosis in CRPC cells
Experiments were conducted to determine the mechanism through
which the inhibition of CXCR2 signalling may increase the
sensitivity of PC3 cells to 17-AAG. Cultured PC3 cells demonstrate
low levels of apoptosis (3–4% of total cells) and necrosis (1–2% of
total cell population) under normal culture conditions. Adminis-
tration of AZ10397767 on its own had a minimal effect on the basal
level of necrosis detected in PC3 cells, whereas it had a modest
effect in increasing the level of apoptosis (Figure 2A and B).
Administration of 1nM 17-AAG alone failed to induce apoptosis
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Figure 1 Inhibition of CXC-chemokine signalling sensitises PC3 but not DU145 cells to ansamycin antibiotics, geldanamycin (GA) and 17-AAG. Survival
curves representing cell viability in PC3 (A and C) cells and DU145 (B and D) cells, as measured by MTT assay, conducted after a 72h exposure to
increasing concentrations of either GA or 17-AAG. The consequence of inhibiting CXC-chemokine signalling on the effect of these compounds on cell
viability was determined by co-administration of the CXCR2 antagonist AZ10397767 (AZ767) at a final concentration of 20nM. Values are expressed as the
mean±s.e.m. of five separate experiments.
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PC3 cells (Figure 2B). Co-administration of AZ10397767 with low-
dose 17-AAG increased the level of apoptosis (Po0.01) but not
necrosis in PC3 cells. The level of apoptosis detected from the
combination of both drugs was similar to the effect of administering
AZ10397767 alone. Administration of high concentrations of 17-AAG
revealed the induction of both apoptosis and necrosis in PC3 cells.
The levels of Hsp90-inhibitor-induced apoptosis and necrosis were
increased when AZ10397767 was co-administered with 1mM 17-AAG;
the increase in necrosis after addition of AZ10397767 was significant
(Po0.05), whereas the increase in apoptosis bordered on statistical
significance. These results suggest that this Hsp90-targeted agent is
cytotoxic to PC3 cells by promoting both necrotic and apoptotic cell
death, mechanisms that seem to be selectively induced in response to
low and high concentrations of 17-AAG, respectively. Our results
suggest that inhibition of CXCR2 signalling increases the efficacy of
17-AAG-induced apoptosis across the entire concentration–re-
sponse curve, whereas it increases necrosis only at higher
concentrations of 17-AAG.
Inhibition of constitutive NF-jB activity enhances
sensitivity of PC3 cells to 17-AAG
Initial experiments were designed to confirm the level of
constitutive NF-kB activity in DU145 and PC3 cells. Using an
NF-kB-specific luciferase reporter assay, we determined a 3.2-fold
higher luciferase activity in transfected PC3 cells relative to
transfected DU145 cells (Po0.01) (Figure 3A). Furthermore,
qPCR-based determination of CXCL8 mRNA confirmed a marked
elevation in the expression of this NF-kB-transcriptional target in
PC3 cells relative to DU145 cells (Po0.001) (Figure 3B). We
previously confirmed an equivalent expression of CXCR1 and
CXCR2 receptors in these cell lines (Murphy et al, 2005).
3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide
assays were established to determine the relationship of constitu-
tive NF-kB activity and the differential sensitivity of PC3 and
DU145 cells to 17-AAG. Constitutive NF-kB activity was inhibited
using a final concentration of 0.1mM BAY11-7082, chosen on the
basis that this concentration of drug exhibited limited toxicity of
its own to these CRPC cells. As before, increasing concentrations of
17-AAG resulted in a concentration-dependent decrease in PC3
cell viability. At each concentration used, the cytotoxicity of 17-
AAG was enhanced in the presence of 0.1mM BAY11-7082
(Figure 3C), promoting a leftwards and parallel displacement of
the concentration–response curve and equating it to a 4.1-fold
increase in IC50 for 17-AAG in these cells. As seen before with
AZ10397767, the presence of BAY11-7082 was shown to sensitise
cells to low concentrations of 17-AAG (e.g., 10nM 17-AAG).
In contrast, administration of BAY11-7082 had no effect in
potentiating the cytotoxicity of 17-AAG in DU145 cells
(Figure 3D). This supports our hypothesis that constitutive
Table 1 Potency of Hsp90-inhibitor cytotoxicity to CRPC cell lines in the absence and presence of the CXCR2 receptor antagonist AZ10397767
IC50 values (nM)I C 20 values (nM)
Cell line Compound
Hsp90
inh alone
Hsp90
inh+AZ10397767
Hsp90 inh
alone
Hsp90
inh+AZ10397767
PC3 GA 29.9±4.2 8.34±2.1 1.67±0.4 0.18±0.2
17-AAG 640±125 185±67 43.7±7.8 0.64±1.8
DU145 GA 1.69±0.08 1.42±0.18 0.42±0.11 0.31±0.09
17-AAG 2.31±0.4 1.81±0.5 0.52±0.2 0.38±0.2
Abbreviations: GA¼geldanamycin: 17-AAG¼17-allylamino-demethoxygeldanamycin.
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Figure 2 Inhibition of CXC-chemokine signalling increases the ability of
17-AAG to induce both apoptosis and necrosis in PC3 cells. (A) Bar graphs
representing flow cytometric analysis of PC3 cells stained with DiOC6(3)
and propidium iodide to assess the consequence of inhibition of CXCR2
receptor signalling to the induction of apoptosis (A) and necrosis (B)b y
72h exposure to 17-AAG (1nM or 1mM). This was determined by co-
administration of the CXCR2 antagonist AZ10397767 at a final
concentration of 20nM. Values are expressed as the mean±s.e.m. of five
separate experiments, *Po0.05; **Po0.01.
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PC3 cells to Hsp90 inhibitors.
The effect of adding BAY11-7082 on the endogenous levels of
CXCL8 in CRPC cells was also confirmed by qPCR and ELISA.
Administration of BAY11-7082 was shown to reduce the endo-
genous mRNA transcript level of vehicle-treated controls for
CXCL8 to 30±8.3% (Po0.01) within 6h (Figure 3E). Similarly, the
rate of CXCL8 secretion from PC3 cells was similarly decreased
after a 6h exposure to BAY11-7082 (Po0.05) (Figure 3F). There-
fore, these experiments establish a link between elevated
constitutive NF-kB activity and increased endogenous CXCL8
expression in the PC3 cell line.
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Figure 3 Inhibition of NF-kB signalling sensitises PC3 but not DU145 cells to 17-AAG. (A) Bar graph comparing the NF-kB transcriptional activity in PC3
and DU145 cells. This was determined using an NF-kB-driven luciferase activity in transiently transfected PC3 and DU145 cells. Cells were co-transfected
with either NF-kB luciferase reporter (2mg) or pGL3 basic vector (2mg), and with Renilla luciferase reporter (0.02mg), and incubated for 72h before
collection and analysis. Transfection efficiencies were adjusted relative to Renilla readouts and luciferase activities were normalised to pGL3 values. Values are
expressed as the mean±s.e.m. of six separate experiments, **Po0.01. (B) Bar graph comparing IL-8 expression levels in PC3 and DU145 cells. Real-time
PCR analysis of IL-8 mRNA transcript levels was used for this comparison. Values are expressed as the mean±s.e.m. of five separate experiments,
***Po0.001. (C and D) Survival curves representing cell viability in PC3 cells (C) and DU145 cells (D), as measured by MTT assay, conducted after a 72h
exposure to increasing concentrations of 17-AAG. The consequence of inhibiting NF-kB signalling on the effect of these compounds on cell viability was
determined by co-administration of the NF-kB antagonist BAY-11-7082 (BAY) at a final concentration of 10nM. Values are expressed as the mean±s.e.m.
of five separate experiments, *P40.05; **Po0.01. (E) Bar graph illustrating relative changes in CXCL8 mRNA transcript levels in PC3 cells after treatment
with BAY-11-7082 for 6h. Values are expressed as the mean±s.e.m. of five separate experiments, **Po0.01. (F) Bar graph illustrating the change in
CXCL8 secretion detected by specific ELISA after treatment with BAY-11-7082 for 6h. Values are expressed as the mean±s.e.m. of four separate
experiments, *Po0.05.
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administration of AZ10397767 with 17-AAG effected NF-kB
transcriptional activity in PC3 cells. Using an NF-kB luciferase
reporter assay, administration of AZ10397767 for 24h was shown
to induce a small but not statistically significant increase in NF-kB
transcriptional activity in PC3 cells. In contrast, neither concen-
tration (1nM or 1mM) increased the activity of this transcription
factor. However, co-administration of AZ10397767 with 1nM 17-
AAG was observed to decrease NF-kB transcriptional activity in
PC3 cells (Po0.05) (Figure 4A). This result was further supported
by analysis of CXCL8 mRNA expression, used in this context as a
readout of NF-kB activity (again determined 24h after the addition
of drugs). By itself, the administration of AZ10397767 was shown
to reduce the expression of CXCL8 mRNA to 73% of that
determined in control cells (Figure 4B). Treatment with 1nM
17-AAG and 1mM 17-AAG promoted concentration-dependent
decreases in the constitutive CXCL8 mRNA levels determined in
cells. The addition of AZ10397767, together with 1nM 17-AAG, had
a pronounced effect in reducing CXCL8 mRNA expression
(Po0.01). No further decrease in CXCL8 mRNA levels was
observed by the addition of AZ10397767 with the higher
concentration of 17-AAG. This suggests that the addition of
AZ10397767 to low concentrations of 17-AAG results in the
maximal repression of NF-kB activity that can be exerted by these
compounds in PC3 cells.
CXC-chemokine signalling induces Hsp90 expression in
CRPC cells through increased Hsp90 gene transcription
Our data indicate that elevated NF-kB activity and CXCL8
expression correlate with reduced sensitivity of PC3 cells to
17-AAG and that inhibition of either NF-kB or CXCR2 signalling
increases the sensitivity of PC3 cells to this Hsp90 inhibitor. The
induction of CXC-chemokine signalling is a well-characterised
response of cells to stress. Therefore, we used qPCR assays and
immunoblotting experiments to determine whether CXCL8
signalling regulated Hsp90 expression in CRPC cells. Addition of
exogenous CXCL8, at a concentration of 3nM, to both PC3 and
DU145 cells resulted in a time-dependent increase in the
expression of Hsp90 mRNA transcripts in both cell lines
(Figure 5A, left and right panels). Although Hsp90 mRNA levels
were increased in both cell lines, there was an apparent difference
in the temporal regulation of Hsp90 transcripts between the two
cell lines; stimulation with CXCL8 was shown to induce rapid
increases in the transcription of the Hsp90 gene (2–4h) in DU145
cells, whereas significant changes were only detected in PC3 cells
16h after treatment with CXCL8.
The link of CXCR2 and NF-kB signalling in underpinning
CXCL8-promoted transcription of the Hsp90 gene in the two CRPC
cell lines was investigated in a further series of experiments. Cells
were stimulated with 3nM CXCL8 in the absence and presence of
20nM AZ10397767 for 24h before analysis of Hsp90 mRNA
transcript levels. Administration of AZ10397767 attenuated the
CXCL8-induced increase in Hsp90 mRNA transcript levels in both
PC3 and DU145 cells (Figure 5B, left and right panel). In addition,
attenuation of NF-kB activity, effected by the co-administration of
5mM BAY11-7082, blocked the CXCL8-promoted increases in
Hsp90 mRNA transcript levels in PC3 cells and DU145 cells
(Figure 5C, left and right panel).
Administration of rh-CXCL8 was also shown to result in an
increased Hsp90 expression at the protein level in DU145 cells,
with peak increases in expression detected 4 and 6h after
stimulation (Figure 6B). In contrast, addition of CXCL8 failed to
potentiate the protein expression of Hsp90 in PC3 cells under these
experimental conditions (Figure 6A). PC3 cells exhibit higher
levels of constitutive CXCL8 expression than do DU145 cells
(Figure 3B), which may explain our inability to observe CXCL8-
induced potentiation of Hsp90 protein expression in these cells. To
test this, AZ10397767 and BAY11-7082 were administered to PC3
and DU145 cells for 16h to determine whether the inhibition of
constitutive CXC chemokine or NF-kB signalling in these cells
altered Hsp90 expression. Densitometry analysis of immunoblots
confirmed that, relative to internal controls, addition of
AZ10397767 reduced the endogenous expression of Hsp90 to 70
and 45% in PC3 and DU145 cells, respectively, compared with that
detected in vehicle-treated controls. Addition of the NF-kB
inhibitor reduced endogenous expression of Hsp90 to B80% of
untreated controls in either cell line (Figure 6C and D).
DISCUSSION
Our results identify a central role of NF-kB activity in modulating
the response of CRPC cells to treatment with ansamycin-based
Hsp90 inhibitors. Comparison of the relative potencies of GA- and
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(A) Bar graph illustrating the effects of 17-AAG and/or AZ10397767
administration on NF-kB transcriptional activity in PC3 cells. Drug-induced
changes in NF-kB-driven luciferase activity were measured and adjusted, as
previously described (legend to Figure 3), 24h after addition of drugs.
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s17-AAG cytotoxicity in the two CRPC cell lines reveals a reduced
sensitivity of PC3 cells to each of the Hsp90-targeted therapeutic
compounds, correlating with the elevated level of constitutive
NF-kB transcriptional activity detected in these cells. Pharmaco-
logical inhibition of this constitutive NF-kB activity in these cells
using BAY11-7082 resulted in an increased sensitisation of cells to
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Figure 5 Interleukin-8 induces Hsp90 gene transcription in CRPC cells. (A) Bar graphs representing real-time PCR analysis of Hsp90 mRNA transcript
levels in PC3 (left panel) and DU145 (right panel) cells after stimulation with 3nM rh-IL-8 for the indicated times. Values are expressed as the mean±s.e.m.
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s17-AAG. In contrast, addition of BAY11-7082 to the more sensitive
DU145 cells had no effect on the potency of 17-AAG, consistent
with the reduced activity of NF-kB detected in this cell line.
Previous pre-clinical and clinical observations have suggested that
Hsp90 inhibitors may be most effective when used as ‘chemo-
modulators’, exploiting their reported capacity to reduce NF-kB
activity to sensitise metastatic cancer cells to chemotherapeutic
and biological agents such as oxaliplatin and TRAIL (Rakitina
et al, 2003). The data presented in this paper indicate that the
efficacy of Hsp90 inhibitors themselves is enhanced when
combined with direct inhibitors of NF-kB activity.
The relevance of NF-kB activity in determining the reduced
sensitivity to ansamycin-based inhibitors of Hsp90 may be two-
fold. First, NF-kB activity is known to confer a cell survival
advantage through regulation of antiapoptotic gene expression.
Thus, silencing of NF-kB activity will reduce the expression of
known antiapoptotic proteins and may concurrently reduce the
transcription and expression of other Hsp90-client proteins, many
of which are critical to the survival of cells with oncogenic
transformation. Our studies also show that the inhibition of NF-kB
activity reduces chemokine-induced increases in mRNA transcript
levels for Hsp90 in the PC3 cell line, indicating that NF-kB
contributes to the transcriptional regulation of the Hsp90 gene in
CRPC cells. Consequently, the elevated NF-kB activity in PC3 cells
may define a multifaceted resistance that functionally antagonises
Hsp90-directed therapeutic agents, initially through a promotion
of compensatory survival signaling, and then through under-
pinning the increased expression of Hsp90 in these cells.
We have shown that exposure to chemotherapy agents induces
NF-kB-driven CXC-chemokine signalling in CRPC cells (Wilson
et al, 2008a,b). These studies also characterise that CXC-
chemokine signalling is coupled to NF-kB transcriptional activity
and thus potentiates chemotherapy-induced activation of this
transcription factor and downstream antiapoptotic gene expres-
sion (Wilson et al, 2008a,b). Inhibition of this stress-induced
CXC-chemokine signalling results in the sensitisation of CaP cells
to chemotherapy and chemotherapy-induced apoptosis (Maxwell
et al, 2007; Wilson et al, 2008a). In this study, we have shown that
pharmacological inhibition of CXCR2 signalling results in a cell-
dependent sensitisation of PC3 cells but not DU145 cells to the
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Figure 6 Interleukin-8 signalling regulates Hsp90 expression in DU145 cells. Immunoblots illustrating the expression of Hsp90 in cell lysates extracted
from (A) PC3 and (B) DU145 cells stimulated with 3nM rh-IL-8 for indicated times. Equal protein loading was confirmed by re-probing the membranes for
GAPDH. (C) Immunoblot detecting levels of Hsp90 expression in the absence and presence of the CXCR2 inhibitor AZ10397767 (20nM) and BAY11-
7082 (5mM), administered to both PC3 and DU145 cells for 16h. (D) Bar graph presenting densitometry analysis of the immunoblots presented in
(C) above. The ratio of Hsp90/GAPDH expression is presented as a percentage of the ratio detected in controls.
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sHsp90 inhibitors, GA and 17-AAG. The capacity of AZ10397767 to
increase ansamycin cytotoxicity in PC3 cells, especially at lower
concentrations of 17-AAG, seems to be related to the reduced
levels of constitutive NF-kB activity detected in PC3 cells receiving
these compounds in combination. This was exemplified by direct
measurements of NF-kB luciferase activity and by using analysis of
CXCL8 gene transcription as a readout of NF-kB activity;
co-administration of AZ10397767 with 1nM 17-AAG attenuated
transcriptional activity and reduced the level of constitutive
CXCL8 mRNA transcripts detected relative to that in untreated
cells or those treated with 17-AAG alone. Accordingly, we propose
on the basis of this and previously published studies that the
blockade of CXCR2 signalling using AZ10397767 (i) acts initially to
inhibit the CXC-chemokine-promoted activation of NF-kB and (ii)
as a consequence of that action, will promote a secondary
response, suppressing NF-kB-promoted regulation of CXCL8 and
anti-apoptotic gene expression. Consequently, the capacity to
perturb NF-kB activity and selectively increase apoptosis levels
provides a primary mechanism of action that explains the capacity
of AZ10397767 to sensitise PC3 cells to Hsp90 inhibitors, especially
at low concentrations of ansamycin compounds. The lower level of
NF-kB activity detected in DU145 cells is consistent with the
inability of either the CXCR2 receptor antagonist or the NF-kB
inhibitor to potentiate the response of these cells to 17-AAG or GA.
We have also shown that CXC-chemokine signalling modulates
the transcription of the Hsp90 gene in CRPC cells through a
CXCR2-, NF-kB-mediated pathway. Interestingly, CXCL8-pro-
moted Hsp90 gene regulation was biphasic in DU145 cells,
suggesting that the regulation of this gene may be promoted
through the action of multiple and temporally regulated transcrip-
tion factors in this cell line. Administration of BAY11-7082
reversed the CXC-chemokine-promoted induction of Hsp90
mRNA transcripts in both cell lines, measured 24h after the
addition of stimulus, indicating that this later phase of transcrip-
tional regulation is probably dependent on chemokine-promoted
NF-kB activity. However, the transcription factor(s) underpinning
the early increase in Hsp90 gene transcription in DU145 cells
remain to be determined. Although an increased Hsp90 gene
transcription was evident from qPCR analysis, immunoblotting
experiments illustrated only quantitative increases in Hsp90
expression in CXCL8-stimulated DU145 cells. Transient blockade
of constitutive CXC-chemokine signalling using the CXCR2
antagonist did reveal decreases in endogenous Hsp90 expression
in both cells, confirming the importance of this receptor in
regulating the transcription and expression of this chaperone
protein. Therefore, as the CXCR2 antagonist reduces Hsp90
expression in both PC3 and DU145 cells, these data suggest that
the sensitising effect of AZ10397767 on the cytotoxicity of Hsp90
inhibitors is more likely explained by the inhibition of constitutive
NF-kB activity, as opposed to a direct modulation of Hsp90
expression.
Understanding the cellular response to Hsp90-targeted
therapeutics is complex and multifaceted, given the extensive list
of client proteins and pathways that are regulated by this protein.
The underlying genetic dysfunction of tumour cells is likely to have
a marked impact in determining the response of cells to Hsp90
inhibitors. For example, a functional retinoblastoma (Rb) protein
has previously been shown to be required to promote ansamycin-
mediated G1 arrest and apoptosis in breast cancer cells. Cells with
defective Rb were subsequently shown to undergo mitotic arrest
before the induction of apoptosis (Munster et al, 2001). In this
study, we showed that cells with increased NF-kB activity are less
sensitive to ansamycins and that inhibiting the constitutive activity
of this transcription factor can sensitise CRPCs to 17-AAG. This
observation may be important for consideration in future strategies
aimed at exploiting Hsp90 inhibitors in the treatment of metastatic
CaP, as nuclear distribution and increased NF-kB activity have
been characterised in a significant proportion of advanced CaP
cases (Fradet et al, 2004; Sweeney et al, 2004). It is already widely
accepted that future clinical development of Hsp90 inhibitors is
likely to see these agents being exploited in combination therapy as
opposed to their use in monotherapy. Therefore, co-administration
with agents that directly perturb NF-kB activity may provide a
useful strategy to sensitise tumours to Hsp90-targeted therapy.
Furthermore, analysis of diagnostic biopsy tissue for evidence of
elevated NF-kB activity may prove to be a useful test to predict
those tumours that are unlikely to show clinical response to
ansamycin-based inhibitors.
In conclusion, these studies add to a series of studies illustrating
the linkage of CXC-chemokine signalling to the development of
chemoresistance in CaP cells. We have shown that constitutive NF-
kB and/or CXC-chemokine signalling decreases the efficacy of
Hsp90 inhibitors in a CRPC cell line that exhibits elevated activity
and expression of these entities. This raises the prospect that
elevated CXC-chemokine expression detected in patient serum
and/or NF-kB activity in diagnostic biopsy specimens may serve as
predictive biomarkers of tumour response to the Hsp90 inhibitors
that are used in treating this disease.
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